



抗人 CD47 流式单抗(FITC)[B6H12.2]

货号: ZX034FT-025; ZX034FT-100 种属反应: 人 CD47 蛋白
抗体亚型: Mouse/IgG1,kappa 荧光标记染料: FITC (Ex 489nm/ Em 515nm)
抗体来源: 杂交瘤细胞 (B6H12.2) 悬浮培养, 亲和层析纯化
保存液成分: PBS pH7.4, 0.01% NaN₃
应用: 免疫荧光, 流式细胞检测
包装规格: 25μg/支 (100μg/支), 0.5mg/mL 贮存运输: 2~8℃, 避光 保质期: 2 年
使用方法: 每 100μL 反应体系 (10⁶ 个细胞) 加入 1μL 抗体, 即 1:100 稀释。建议优化稀释比例。

简介:

本公司抗体产品经先进的杂交瘤细胞 (或 CHO 细胞) 无血清悬浮培养技术表达, 避免腹水表达中宿主抗体的污染。经亲和层析纯化, 抗体纯度可达 95% 以上, 且可保持较高的抗体活性。本产品单克隆抗体 (B6H12.2) 可特异性结合小鼠细胞表面蛋白 CD47, 并经 FITC 标记。

注意事项: 本试剂只适用于科研应用, 不可用于临床检测。

参考文献:

- 1.Dheilily E, Moine V, Broyer L, et al. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies. *Mol Ther.* 2017;25(2):523–533.
- 2.Soto-Pantoja DR, Kaur S, Roberts DD. CD47 signaling pathways controlling cellular differentiation and responses to stress. *Crit Rev Biochem Mol Biol.* 2015;50(3):212–230.
- 3.Golubovskaya V, Berahovich R, Zhou H, et al. CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. *Cancers (Basel).* 2017;9(10):139. Published 2017 Oct 21.
- 4.Kauder SE, Kuo TC, Harrabi O, et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. *PLoS One.* 2018;13(8):e0201832. Published 2018 Aug 22.

企业名称: 浙江正熙生物医药有限公司

企业地址: 中国浙江省湖州市德清县阜溪街道长虹东街 926 号千人计划产业园 1 号楼

企业网址: <https://www.zxbiopharm.com/>

联系方式: 0572-8232782



Anti-Human CD47 Monoclonal Antibody (FITC) [B6H12.2]

Catalog: ZX034FT-025; ZX034FT-100 **Antigen:** Against Human CD47
Antibody Host: Mouse/IgG1,kappa **Fluorescent Labeling Dye:** FITC (Ex 489nm/ Em 515nm)
Antibody Origin: Hybridomas (Clone: B6H12.2) Culture, Affinity Purification
Formulation: PBS pH7.4, 0.01% NaN₃
Application: FC (Flow Cytometry), IF (Immunofluorescence)
Package Specification: 25µg/Vial(100µg/Vial), 0.5mg/mL **Guarantee Period:** 2 years
Storage & Handling: stored between 2°C and 8°C, protected from light exposure. **Do not freeze.**
Recommended Usage: ≤1 µL /10⁶ cells in 100 µl volume per test (Maximum dilution 1:100)

Product Information:

To improve the quality of monoclonal antibodies for research purpose, ZXBio develops novel cell culturing technologies to grow hybridomas/CHO cells in serum-free condition. This method is superior to traditional ascites production method, which always contaminates the purified antibodies with host proteins. Using affinity purification, ZXBio is able to purify monoclonal antibodies at a purity higher than 95%.

Anti-Human CD47 Monoclonal Antibody [B6H12.2] specifically binds mouse T cell membrane CD47 surface antigen and the product is labeled with FITC.

Application Notes: For research use only, Not for use in diagnostic procedures.

Reference:

- 1.Dheilly E, Moine V, Broyer L, et al. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies. *Mol Ther.* 2017;25(2):523–533.
- 2.Soto-Pantoja DR, Kaur S, Roberts DD. CD47 signaling pathways controlling cellular differentiation and responses to stress. *Crit Rev Biochem Mol Biol.* 2015;50(3):212–230.
- 3.Golubovskaya V, Berahovich R, Zhou H, et al. CD47-CAR-T Cells Effectively Kill Target Cancer Cells and Block Pancreatic Tumor Growth. *Cancers (Basel).* 2017;9(10):139. Published 2017 Oct 21.
- 4.Kauder SE, Kuo TC, Harrabi O, et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. *PLoS One.* 2018;13(8):e0201832. Published 2018 Aug 22.

Corporation Name: ZXBio Co., Ltd.

Corporation Address: No. 926 Changhong East Rd, Deqing Xian, Huzhou Shi, Zhejiang, China

Corporate Website: <https://www.zxbiopharm.com/>

Corporate Phone: 0572-8232782